Carboplatin Side Effects
Applies to carboplatin: intravenous powder for solution, intravenous solution.
Intravenous route (Solution; Powder for Solution)
Bone marrow suppression with carboplatin is dose-related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect. Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin administration.
Serious side effects of Carboplatin
Along with its needed effects, carboplatin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.
Check with your doctor as soon as possible if any of the following side effects occur while taking carboplatin:
- Pain at place of injection
- Black, tarry stools
- blood in urine or stools
- cough or hoarseness, accompanied by fever or chills
- fever or chills
- lower back or side pain, accompanied by fever or chills
- numbness or tingling in fingers or toes
- painful or difficult urination, accompanied by fever or chills
- pinpoint red spots on skin
- skin rash or itching
- unusual bleeding or bruising
- unusual tiredness or weakness
- Blurred vision
- ringing in ears
- sores in mouth and on lips
Other side effects of Carboplatin
Some side effects of carboplatin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Nausea and vomiting
- unusual tiredness or weakness
This medicine may cause a temporary loss of hair in some people. After treatment with carboplatin has ended, normal hair growth should return.
For Healthcare Professionals
Applies to carboplatin: intravenous powder for injection, intravenous solution.
Rare (less than 0.1%): Febrile neutropenia
Frequency not reported: Bone marrow failure, hemolytic-uremic syndrome[Ref]
Very common (10% or more): Nausea (93%), vomiting (84%), adverse GI effects (50%), abdominal pain
Common (1% to 10%): Mucositis, diarrhea, constipation
Very common (10% or more): Central neurotoxicity (26%), peripheral neuropathy (15%)
Common (1% to 10%): Other sensory side effects, paresthesia, decrease of osteotendinous reflexes, sensory disturbance, dysgeusia
Very common (10% or more): Alkaline phosphatase elevations (29%), SGOT elevations (20%), aspartate aminotransferase increased, liver function test abnormal
Common (1% to 10%): Bilirubin elevations[Ref]
Very common (10% or more): Blood urea elevations (17%), creatinine renal clearance decreased[Ref]
Very common (10% or more): Pain (44%), asthenia (41%), ototoxicity (12%)
Common (1% to 10%): Asthenia
Frequency not reported: Malaise[Ref]
Common (1% to 10%): Hypersensitivity, anaphylactoid type reaction[Ref]
Very common (10% or more): Magnesium loss (61%), potassium loss (16%), calcium loss (16%), sodium loss (10%)
Rare (less than 0.1%): Hyponatremia
Rare (less than 0.1%): Visual disturbance (including rare cases of loss of vision)[Ref]
Very common (10% or more): Infection (14%)
Frequency not reported: Injection site necrosis, injection site reaction, injection site extravasation, injection site erythema
Common (1% to 10%): Musculoskeletal disorder[Ref]
Common (1% to 10%): Urogenital disorder[Ref]
Frequency not reported: Neoplasms (e.g., benign, malignant, unspecified) including cysts and polyps[Ref]
Common (1% to 10%): Respiratory disorder, interstitial lung disease, bronchospasm
Common (1% to 10%): Cardiovascular disorder
Very common (10% or more): Alopecia (49%), skin disorder
Frequently asked questions
- Why give Taxol (Paxel) before carboplatin?
- How does carboplatin stop cancer?
- Does carboplatin cause neuropathy?
More about carboplatin
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Dosage information
- During pregnancy
- Drug class: alkylating agents
- En español
Related treatment guides
1. Kerr DJ, Lewis C, O'Neill B, et al. The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol Oncol. 1990;8:59-63.
2. Multum Information Services, Inc. Expert Review Panel
3. Product Information. Paraplatin (carboplatin). Bristol-Myers Squibb. 2001.
4. Product Information. Carboplatin (carboplatin). Sun Pharmaceutical Industries. 2019.
5. McDonald BR, Kirmani S, Vasquez M, Mehta R. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med. 1991;90:386-91.
6. Deray G, Ben-Othman T, Brillet G, Baumelou B, Gabarre J, Baumelou A, Binet JL, Jacobs C. Carboplatin-induced acute renal failure. Am J Nephrol. 1990;10:431-2.
7. Mulder PO, Sleijfer DT, de Vries EG, Uges DR, Mulder NH. Renal dysfunction following high-dose carboplatin treatment. J Cancer Res Clin Oncol. 1988;114:212-4.
8. Chevreau C, Thomas F, Couteau C, Dalenc F, Mourey L, Chatelut E. Ototoxicity of high-dose Carboplatin. J Clin Oncol. 2005;23:3649-50.
9. Windom HH, McGuire WP, Hamilton RG, Adkinson NF. Anaphylaxis to carboplatin: a new platinum chemotherapeutic agent. J Allergy Clin Immunol. 1992;Oct:681-3.
10. Weidmann B, Mulleneisen N, Bojko P, Niederle N. Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer. 1994;73:2218-22.
11. Planner RS, Weerasiri T, Timmins D, Grant P. Hypersensitivity reactions to carboplatin. J Natl Cancer Inst. 1991;83:1763-4.
12. Tonkin KS, Rubin P, Levin L. Carboplatin hypersensitivity: case reports and review of the literature. Eur J Cancer. 1993;29a:1356-7.
13. Sood AK, Gelder MS, Huang SW, Morgan LS. Anaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol Oncol. 1995;57:131-2.
14. Broome CB, Schiff RI, Friedman HS. Successful desentization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol. 1996;26:105-10.
15. O'Brien MER, Tonge K, Blake P, et al. Blindness associated with high-dose carboplatin. Lancet. 1991;339:558.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.